Invizius Awarded Major Biomedical Catalyst Grant to bring Anti-Inflammatory Haemodialysis Treatment to The Clinic

BioCity, Scotland, 30th March 2022

  •  £1 million grant will support first-in-human clinical trials of H-Guard

Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of haemodialysis, to the clinic. The funds will be used towards H-Guard’s First-in-Man safety study commencing in 2022.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH